What drove the SKIN.SW stock move today?

SKIN.SW stock rose **9.85%** to **CHF35.70** on 28 Jan 2026 due to a volume spike of **2756.00** and renewed interest in Cassiopea’s dermatology pipeline. No formal earnings release was reported, so market momentum likely reflected clinical or sector chatter.

What is Meyka AI's rating for SKIN.SW stock?

Meyka AI rates SKIN.SW with **58.66** points, grade **C+** and a **HOLD** suggestion. The grade considers benchmark and sector comparisons, financial growth, key metrics, and analyst signals.

What price targets and forecast exist for SKIN.SW stock?

Meyka AI's forecast model projects a conservative **CHF32.00**, base **CHF40.00**, and bullish **CHF52.00**. The base target implies **11.99%** upside versus the close of **CHF35.70**. Forecasts are model-based and not guarantees.

How liquid is SKIN.SW stock on the SIX?

SKIN.SW trading shows low absolute volume but above-average activity today: **volume 2756.00** vs **avgVolume 1818.00**, giving a relative volume around **1.52**. Thin liquidity can widen spreads and increase volatility.

CH Stocks

SKIN.SW Cassiopea S.p.A. (SIX) up 9.85% to CHF35.70 on 28 Jan 2026: volume spike signals momentum

ByHuzaifa Zahoor January 29, 2026

SKIN.SW stock led high-volume moves on 28 Jan 2026, rising 9.85% to CHF35.70 as trading closed on the SIX. The session showed a clear intraday jump from CHF32.00 to CHF36.00, with volume 2756.00 versus an average of 1818.00. Investors reacted to clinical-stage catalysts and short-term momentum. We summarise why the jump matters, link fundamentals to price, and offer Meyka AI’s model-based outlook for Cassiopea S.p.A. in Switzerland